Investigator Initiated Trial to Evaluate Efficacy and Safety of LAENNEC (Human Placenta Hydrolysate) Administered by Ultrasonography Guided Subacromial Bursa Injection in Patients With Shoulder Impingement Syndrome

Exclusion Criteria

• •1. A person who appears in the movement of two or more shoulder joints with more than 50% of the joint movement limit on the passive shoulder joint operation scope test.
• •2. Those who have confirmed the rupture of the entire layer by ultrasound
• •3. Those with serious damage to the shoulders and the past power
• •4. Those who have suspected fractures, dislocations, degenerative arthritis, and calcification in the shoulder radiation test in the shoulder radiation test.
• •5. Those who complain of shoulder pain due to stroke, spinal cord injury, and other surgery
• •6. Those with other shoulder diseases other than fifty dogs (rheumatoid arthritis, osteoarthritis, bone defect injuries, malignant tumors, etc.)
• •7. Those who are accompanied by diseases of cervical spine or other upper limbs that have a significant effect on the shoulder
• •8. Those who have performed steroid injections in the joint steel within 3 months of participation in clinical trials
• •9. Those who have administered anti -inflammatory drugs within two weeks of participation in clinical trials
• •10. Those with all other joint diseases that have musculoskeletal diseases that may affect effective evaluation, or that it is impossible to participate in this clinical trial.
• •11. Those who are diagnosed with mental illness and taking drugs
• •12. Pregnant women and lactation departments, fertility women who are not willing to contraceptive during the clinical trial period
• •13. Those who have received medication, oriental medicine, physical therapy, and injection treatment in relation to shoulder pain within the last two weeks 14 Those who are participating in other clinical trials during screening
• •15\. Those who determine that other testors are inadequate